相似文献
1
Current medical treatment for tuberculosis.
BMJ. 2002 Nov 30;325(7375):1282-6. doi: 10.1136/bmj.325.7375.1282.
2
M tuberculosis drug resistance in AIDS.
Lancet. 1997 Jan 4;349(9044):61; author reply 61-2. doi: 10.1016/S0140-6736(05)62201-5.
3
The good news and the bad news about multidrug-resistant tuberculosis.
Clin Infect Dis. 1995 Nov;21(5):1265-6. doi: 10.1093/clinids/21.5.1265.
4
Immune reconstitution syndrome following initiation of antiretroviral therapy in a patient with HIV infection and multidrug-resistant tuberculosis.
Indian J Chest Dis Allied Sci. 2005 Oct-Dec;47(4):299-304.
5
Drug resistance in Mycobacterium tuberculosis.
Eur Respir J Suppl. 1995 Sep;20:701s-713s.
6
First case of primary multidrug-resistant pulmonary tuberculosis in a HIV-infected patient in Hungary.
Eur J Clin Microbiol Infect Dis. 2003 Oct;22(10):635-6. doi: 10.1007/s10096-003-1008-1. Epub 2003 Sep 12.
7
Improved outcomes for patients with multidrug-resistant tuberculosis.
Clin Infect Dis. 1995 Nov;21(5):1238-44. doi: 10.1093/clinids/21.5.1238.
8
Hanging in there for a new TB drug.
S Afr Med J. 2000 Apr;90(4):336-7.
9
Case records of the Massachusetts General Hospital. Case 18-2009. A 24-year-old woman with AIDS and tuberculosis with progressive cough, dyspnea, and wasting.
N Engl J Med. 2009 Jun 4;360(23):2456-64. doi: 10.1056/NEJMcpc0902226.
10
Drug resistant tuberculosis: back to sanatoria, surgery and cod-liver oil?
Eur Respir J. 1995 Jul;8(7):1073-5. doi: 10.1183/09031936.95.08071073.
引用本文的文献
1
Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
BMC Infect Dis. 2022 Nov 21;22(1):870. doi: 10.1186/s12879-022-07861-x.
2
Targeting the cytochrome bc complex for drug development in M. tuberculosis: review.
Mol Divers. 2022 Oct;26(5):2949-2965. doi: 10.1007/s11030-021-10335-y. Epub 2021 Nov 11.
3
A Simple Work-Up-free, Solvent-free Approach to Novel Amino Acid Linked 1,4-Disubstituted 1,2,3-Triazoles as Potent Antituberculosis Agents.
ACS Omega. 2020 Nov 11;5(46):29830-29837. doi: 10.1021/acsomega.0c03862. eCollection 2020 Nov 24.
4
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
Bioorg Med Chem Lett. 2019 Sep 15;29(18):2695-2699. doi: 10.1016/j.bmcl.2019.07.012. Epub 2019 Jul 10.
5
Combating Tuberculosis Infection: A Forbidding Challenge.
Indian J Pharm Sci. 2016 Jan-Feb;78(1):8-16. doi: 10.4103/0250-474x.180243.
6
Directly observed therapy for treating tuberculosis.
Cochrane Database Syst Rev. 2015 May 29;2015(5):CD003343. doi: 10.1002/14651858.CD003343.pub4.
7
Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
Int J Tuberc Lung Dis. 2014 Aug;18(8):912-8. doi: 10.5588/ijtld.13.0028.
8
Unusual isolated tubercolous epididymitis. Case report.
G Chir. 2014 May-Jun;35(5-6):134-6.
9
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10.
10
A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
J Clin Immunol. 2013 Nov;33(8):1360-75. doi: 10.1007/s10875-013-9949-3. Epub 2013 Oct 20.
本文引用的文献
1
Tuberculosis therapy: past, present and future.
Eur Respir J Suppl. 2002 Jul;36:87s-94s. doi: 10.1183/09031936.02.00309102.
2
HIV-1/AIDS and the control of other infectious diseases in Africa.
Lancet. 2002 Jun 22;359(9324):2177-87. doi: 10.1016/S0140-6736(02)09095-5.
3
Issues in the treatment of Mycobacterium tuberculosis in patients with human immunodeficiency virus infection.
AIDS. 2001;15 Suppl 5:S203-12. doi: 10.1097/00002030-200100005-00024.
4
5
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.
Nature. 2000 Aug 17;406(6797):735-8. doi: 10.1038/35021074.
6
Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47. doi: 10.1164/ajrccm.161.supplement_3.ats600.
7
Modeling the epidemiology and economics of directly observed therapy in Baltimore.
Int J Tuberc Lung Dis. 2000 Mar;4(3):201-7.
8
9
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.
Am J Respir Crit Care Med. 1998 Jul;158(1):157-61. doi: 10.1164/ajrccm.158.1.9712001.
10
Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel.
JAMA. 1998 Mar 25;279(12):943-8. doi: 10.1001/jama.279.12.943.
Zotero 插件